China Ensures Drug Supply For Snow Storm Crisis
This article was originally published in PharmAsia News
China's State FDA and relevant health departments are revising their operations to ensure an adequate production and supply of drugs during the current snowstorm crisis. Furthermore, any incidence of counterfeit products will be investigated and severely dealt with. Drugs identified include those for respiratory and coronary diseases, frostbite, and orthopedic injuries. The government is also stockpiling large quantities of injection doses, blood products and vaccines. So far there has been no report of drug safety incidents. Pfizer has donated over 1 million yuan's ($139,053) worth of its antibiotic Zithromax to help victims in snow-hit areas. (Click here for more - Chinese Language)
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.